hydroxyurea has been researched along with organophosphonates in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delaisse, JM; Eeckhout, Y; Vaes, G | 1 |
| Elson, P; Hsieh, P; Oken, MM; Trump, DL; Witte, RS | 1 |
| Merigan, TC; Palmer, S; Shafer, RW | 1 |
| De Clercq, E; Neyts, J | 1 |
| Anton, KE; Cherrington, JM; Lamy, PD; Margot, NA; Miller, MD; Mulato, AS; Quan, Y; Salomon, H; Wainberg, MA | 1 |
| Crabbs, C; Greenhouse, J; Lewis, MG; Lisziewicz, J; Lori, F; Silvera, P; Tinelli, C; Varga, G; Wagner, W; Xu, J; Yalley-Ogunro, J; Zinn, DE | 1 |
| Carr, A; Chuah, J; Cooper, DA; Doong, N; French, M; Hoy, J; Hudson, J; Law, M; Mallal, S; Smith, D | 1 |
| Barditch-Crovo, P; Coakley, DF; Collier, A; Deeks, SG; McGowan, I; Miller, M; Smith, A | 1 |
| Ait Arkoub, Z; Arnulf, B; Chebbi, F; Fillet, AM; Lefrere, F; Varet, B | 1 |
| Bendele, RA; Richardson, FC | 1 |
| Kast, RE | 1 |
| Pagano, JS; Raab-Traub, N; Wakisaka, N; Yoshizaki, T | 1 |
| Boivin, G; Sergerie, Y | 1 |
4 trial(s) available for hydroxyurea and organophosphonates
| Article | Year |
|---|---|
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imides; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Naphthalimides; Organophosphonates; Survival Rate; Treatment Outcome | 1996 |
PMPA trials recruiting.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 1998 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideoxynucleosides; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxyurea; Insulin Resistance; Lipodystrophy; Male; Middle Aged; Nevirapine; Organophosphonates; Quality of Life; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2001 |
Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyurea; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2001 |
10 other study(ies) available for hydroxyurea and organophosphonates
| Article | Year |
|---|---|
Bone-resorbing agents affect the production and distribution of procollagenase as well as the activity of collagenase in bone tissue.
Topics: Acetazolamide; Animals; Bone and Bones; Bone Resorption; Calcitonin; Calcitriol; Cells, Cultured; Collagenases; Cycloheximide; Dinoprostone; Enzyme Precursors; Fetus; Heparin; Hydroxyurea; Interleukin-1; Kinetics; Mice; Microbial Collagenase; Organophosphonates; Osteoclasts; Parathyroid Hormone; Prostaglandins E; Recombinant Proteins; Tretinoin; Triamcinolone; Tumor Necrosis Factor-alpha | 1988 |
Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.
Topics: Adenine; Anti-HIV Agents; Antineoplastic Agents; Didanosine; DNA, Viral; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Hydroxyurea; Inhibitory Concentration 50; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 1999 |
Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.
Topics: Animals; Antiviral Agents; Cell Division; Cell Survival; Chlorocebus aethiops; Drug Synergism; Herpesvirus 1, Human; HIV Infections; Humans; Hydroxyurea; Nucleic Acid Synthesis Inhibitors; Nucleosides; Organophosphonates; Purine Nucleosides; Pyrimidine Nucleosides; Vero Cells; Virus Replication | 1999 |
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Topics: Adenine; Anti-HIV Agents; Drug Resistance; HIV Reverse Transcriptase; HIV-1; Hydroxyurea; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir | 1999 |
Control of SIV rebound through structured treatment interruptions during early infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Hydroxyurea; Lymphocyte Activation; Macaca mulatta; Organophosphonates; Organophosphorus Compounds; Random Allocation; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Viral Load; Viremia; Virus Replication | 2000 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Combined Modality Therapy; Cyclosporine; Cytarabine; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Fatal Outcome; Foscarnet; Graft vs Host Disease; Herpes Genitalis; Herpes Simplex; Humans; Hydroxyurea; Immunocompromised Host; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Simplexvirus; Transplantation Conditioning; Whole-Body Irradiation | 2001 |
Adefovir nephrotoxicity and mitochondrial DNA depletion.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; DNA, Mitochondrial; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Kidney Tubules; Mitochondria; Organophosphonates; Renal Insufficiency; Stavudine | 2002 |
Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation.
Topics: Adenine; Adenylyl Cyclases; Anti-HIV Agents; Cell Division; Cyclooxygenase Inhibitors; Humans; Hydroxyurea; Immunotherapy; Lipoxygenase Inhibitors; Lymphocytes; Neoplasms; Organophosphonates; Organophosphorus Compounds; Tenofovir; Tumor Necrosis Factor-alpha; Up-Regulation | 2003 |
Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cidofovir; Cytosine; Drug Interactions; Enzyme Inhibitors; Epstein-Barr Virus Infections; Humans; Hydroxamic Acids; Hydroxyurea; Mice; Mice, Nude; Nasopharyngeal Neoplasms; Organophosphonates; Ribonucleotide Reductases; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytosine; DNA-Directed DNA Polymerase; Drug Combinations; Drug Resistance, Viral; Foscarnet; Herpesvirus 1, Human; Humans; Hydroxyurea; Mutation; Organophosphonates; Ribonucleotide Reductases; Thymidine Kinase | 2008 |